Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:41 AM
Ignite Modification Date:
2025-12-25 @ 12:41 AM
NCT ID:
NCT01421667
Eligibility Criteria:
Inclusion Criteria:
* Histologically-confirmed NHL (DLBCL only for Parts B and C)
* Relapsed or refractory disease following at least 1 prior systemic therapy
* Measurable disease of at least 1.5 cm as documented by CT
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Exclusion Criteria:
* History of another primary invasive malignancy that has not been in remission for at least 3 years
* Current diagnosis of systemic or cutaneous anaplastic large cell lymphoma or mycosis fungoides
* B cell lymphoma previously treated with only single-agent rituximab (for patients receiving brentuximab vedotin only) or corticosteroids as monotherapy
* Known cerebral/meningeal disease
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
6 Years
Study:
NCT01421667
Study Brief:
Protocol Section:
NCT01421667